 |
|
|
| |
Efficacy and safety of MK-5172 and MK-8742 ± RIBAVIRIN IN Hepatitis C Genotype 1 Infected Patients with cirrhosis or previous null response: the C-WORTHY Study
|
| |
| |
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Eric Lawitz1, Christophe Hezode2, Edward Gane3, Edward Tam4, Martin Lagging5, Luis Balart6, Lorenzo Rossaro7, Reem Ghalib8, Melissa Shaughnessy9, Peggy Hwang9, Janice Wahl9, Michael Robertson9, Barbara Haber9
1The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA;
2Henri Mondor Hospital, University of Paris-Est, Creteil, France; 3Auckland Clinical Studies, Grafton, Auckland, New Zealand; 4LAIR Centre, Vancouver, Canada; 5Institute of Biomedicine, University of Gothenburg, Sweden; 6Tulane University School of Medicine, New Orleans, LA, USA; 7University of California, Davis Medical Center, Sacramento, CA, USA; 8Texas Clinical Research Institute, Arlington, TX, USA;
9Merck & Co., Inc., Whitehouse Station, NJ, USA
|
| |
|
|
|
|
|
